Ethnic Differences in DNA Methyltransferases Expression in Patients with Systemic Lupus Erythematosus
Systemic lupus erythematous (SLE) is a systemic autoimmune inflammatory disease with both genetic and epigenetic etiologies. Evidence suggests that deregulation of specific genes through epigenetic mechanisms may be a contributing factor to SLE pathology. There is increasing evidence that DNA methyltransferase activity may be involved. This study demonstrated modulation in expression of DNA methyltransferases (DNMTs) according to ethnicity in patients diagnosed with SLE. Furthermore, differential expression in one of the DNMTs was found in a subset of lupus patients on dehydroepiandrosterone (DHEA) therapy.
Real-time PCR analyses of DNMT1, DNMT3A and DNMT3B in peripheral blood mononuclear cells from a cohort of African American and European American lupus and non-lupus women were conducted. Also, global DNA methylation was assessed using the MethylFlashTM methylated quantification colorimetric assay.
Significant increase in DNMT3A (p < 0.001) was shown in lupus patients when compared to age-matched healthy controls. This increase was associated with a higher SLEDI index. More striking was that expression levels for African American (AA) women were higher than European American women in the lupus populations. A subset of AA women on DHEA therapy showed a significant decrease (p < 0.05) in DNMT3A expression in comparison to lupus patients not on the therapy. DHEA is an androgenic steroid found in low levels in the serum of lupus patients. Supplementation of this hormone has been shown to be beneficial to some lupus patients. DHEA was not shown to effect DNMT1 or DNMT3B expression. Increased expression was also noted in DNMT3B (p < 0.05) in lupus patients compared to age-matched healthy controls. However, no significant difference was noted in DNMT1 (p = 0.2148) expression between lupus patients and healthy controls. Although increases were detected in de novo methyltransferases, a global decrease (p < 0.001) in 5-methycytosine was observed in lupus patients when compared to age-matched healthy controls.
These findings suggest that epigenetic changes may play a critical role in the manifestations of the disease observed among ethnic groups, particularly African American women who often have a higher incidence of lupus. DHEA therapy effects on DNMT3A expression in AA women warrant further investigation in a larger population.
- Lahita RG. Systemic lupus erythematosus. Amsterdam: Elsevier; 2004.
- Lupus Foundation of American. Statistics about Lupus.
- Foundation, S.L.E.L., Facts about gender and racial disparities in Lupus: Lupus targest women and minorities.
- Ramos-Casals M, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Med (Baltimore). 2008;87(6):345–64. CrossRef
- Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29(7):707–16. CrossRef
- Calero I, Sanz I. Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med. 2010;10(54):416–24.
- Kocis P. Prasterone. Am J Health Syst Pharm. 2006;63(22):2201–10. CrossRef
- Merrill JT. Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. Expert Opin Investig Drugs. 2003;12(6):1017–25. CrossRef
- Ãstensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2000;9(8):566–72. CrossRef
- Jabin D, Kumar S, Gow PJ. Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline. N Z Med J. 2010;123(1324):67–73.
- Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J. 2006;12(1):3.
- Mitka M. Treatment for Lupus, first in 50 years, offers modest benefits, hope to patients. J Am Med Assoc. 2011;305(17):1754–5. CrossRef
- Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40(1):66–73. CrossRef
- Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematous. Current Rheumatol Rep. 2008;10(4):286–91. CrossRef
- Luo Y, et al. Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;159(4):827–33. CrossRef
- Ballestar E, Esteller M, Richardson BC. The epigentic face of systemi lupus erythematosus. J Immunol. 2006;176:143–7.
- Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol. 1986;17:456–70. CrossRef
- Zhou Y, et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol. 2009;132(3):362–70. CrossRef
- Wei-Min S, et al. The effect of DNMTs and MBPs on hypomethylation in systemic lupus erythematosus. J Dermatol Sci. 2009;53(3):236–8. CrossRef
- Fisher CL, Fisher AG. Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr Opin Genet Dev. 2011;21(2):140–6. CrossRef
- Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol. 2003;109(1):37–45. CrossRef
- Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol. 2003;109(1):17–28. CrossRef
- Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:127–36. CrossRef
- Zouali M. Epigenetics in lupus. Ann N Y Acad Sci. 2011;1217(1):154–65. CrossRef
- Gowher H, et al. De Novo Methylation of Nucleosomal DNA by the Mammalian Dnmt1 and Dnmt3A DNA Methyltransferasesâ€. Biochemistry. 2005;44(29):9899–904. CrossRef
- Fatemi M, et al. The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. J Mol Biol. 2001;309(5):1189–99. CrossRef
- Hedrich CM, Tsokos GC. Epigenetic mechanims in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med. 2011;17(12):714–22. CrossRef
- Hughes T, Sawalha AH. The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther. 2011;13(245):1–11.
- Sckigawa I, Okada M, Ogasawara H, Hishikawa T, Hashimoto H. DNA methylation in systemic lupus erythematosus. Lupus. 2003;12:79–85. CrossRef
- Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmune, aging and cancer. J Nutrition. 2002;132:2401–5.
- Zhao S, Long H, Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol. 2010;39:3–9. CrossRef
- Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol. 2003;3(4):344–51. CrossRef
- Astrid S, et al. The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors. ChemMedChem, 2009. 9999(9999): p. NA.
- Cunliffe VT. Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev. 2008;18(5):404–10. CrossRef
- Ng K, et al. Xist and the order of silencing. EMBO Rep. 2007;8(1):34–9. CrossRef
- Cheng X, Blumenthal RM. Mammalian DNA Methyltransferases: a structural perspective. Structure. 2008;16(3):341–50. CrossRef
- Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011;6:593–601. CrossRef
- Lai G, Bromberg JS. Eipigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009;114(18):3727–34. CrossRef
- Lu Q, Wu A, Richardson BC. Demethylaion of the same promoter sequence increaseas CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol. 2005;174(10):6212–9.
- Lai G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009;182(1):259–73.
- Liu CC, et al. Global DNA methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus. Lupus. 2011;20(2):131–6. CrossRef
- Zhu X, et al. Analysis of associations between the patterns of global DNA hypomethylation and expression of DNA methyltransferase in patients with systemic lupus erythematosus. Int J Dermatol. 2011;50(6):697–704. CrossRef
- Nagar M, et al. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25âˆ’CD4+ T cells. Int Immunol. 2008;20(8):1041–55. CrossRef
- Makar KW, et al. Active recruitment of DNA methyltransferases regulates interleukin 4 in thymocytes and T cells. Nat Immunol. 2003;4(12):1183–90. CrossRef
- Hodge DR, et al. IL-6 Enhances the Nuclear Translocation of DNA Cytosine-5-Methyltransferase 1 (DNMT1) via Phosphorylation of the Nuclear Localization Sequence by the AKT Kinase. CANCER GENOMICS PROTEOMICS. 2007;4(6):387–98.
- Schonthaler HB, Guinea-Viniegra J, Wagner EF. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis. 2011;70 Suppl 1:1109–12. CrossRef
- Ethnic Differences in DNA Methyltransferases Expression in Patients with Systemic Lupus Erythematosus
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of Clinical Immunology
Volume 33, Issue 2 , pp 342-348
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- DNA methyltransferases
- Industry Sectors